This biomarker is also known as:
- basal cell adhesion molecule (Lu and Au blood groups),
- Auberger B antigen,
- Lutheran antigen,
- basal cell adhesion molecule (Lutheran blood group),
- Basal cell adhesion molecule,
- F8/G253 antigen,
- Lutheran blood group glycoprotein,
- B-CAM cell surface glycoprotein,
- Lutheran blood group (Auberger b antigen included),
View in BioMuta
Lutheran blood group glycoprotein is a member of the immunoglobulin superfamily and a receptor for the extracellular matrix protein, laminin alpha-5. The protein contains five, N-terminus, extracellular immunoglobulin domains, a single transmembrane domain, and a short, C-terminal cytoplasmic tail. This protein may play a role in epithelial cell cancer and in vaso-occlusion of red blood cells in sickle cell disease. It may also play a role in intracellular signalling. BCAM has wide tissue distribution (highest in the pancreas and very low in brain) and is closely associated with the basal layer of cells in epithelia and the endothelium of blood vessel walls. Two transcript variants encoding different isoforms have been found for this gene.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
This biomarker is currently being annotated or is under review.
You must be logged in
or do not have permission to view any additional information. Contact Heather Kincaid at
if you should have access to this biomarker.
No associated publications found.
No associated resources found.
Update: Pre-application webinar information now available.
The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.
The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.
The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.